ACTH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-20. Anything still debated is marked as such rather than presented as settled.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
== Antidepressant research == Two meta-analyses of preliminary clinical trials evaluating the efficacy of St. John's wort for treating mild-to-moderate depression indicated a response similar to selective serotonin reuptake inhibitors and with better tolerance, although the long-term generalization of study results was limited by the short duration (4–12 weeks) of reviewed studies.
Cliffe began directly contacting Half-Life mappers and reached out to people who had previously submitted maps to Radium, a Half-Life mapping site. A contest was held to select maps for the initial beta, though some maps selected were later discarded. Before the first beta's official release, a pre-beta build was leaked online, which potentially accelerated the release of the mod. The first beta, released on June 18, 1999, featured a hostage rescue scenario, 9 weapons, 4 maps, and one player model per side. Jess Cliffe reported that the release was well received by the community. Beta 2 and Beta 3 followed, adding new weapons, maps, and factions. Beta 3 introduced the removal of kill counts from the scoreboard, which was controversial and later reversed. Beta 4 introduced the bomb defusal scenario. The interest in the game drew numerous players to Cliffe's website, which helped both him and Le make revenue from advertisements hosted on the site. Another website related to Counter-Strike, a fansite named CS-Nation, was launched by John "rizzuh" Jensen as a source for information about the game, news updates, and skins. In late 1999, Minh Le began working at Barking Dog Studios while finishing his studies. When Valve Software learned of this, they asked Barking Dog to assist in developing Beta 5, offering to finance the project and acquire the game's intellectual property. Barking Dog mainly handled development, as Le was occupied with his university studies. Valve contributed by cleaning up code, fixing bugs, and enhancing the interface.
Dekaranger, Ban acquires a variant of the SP License called the Fire Squad License (ファイヤースクワッドライセンス, Faiyā Sukuwaddo Raisensu), which allows him to transform Murphy K-9 into his armor to assume Battlizer Mode (バトライザーモード, Batoriza Mōdo) where he gains a rocket booster pack and a pair of siren lasers. In this form, he wields a sword/rifle hybrid, which allows him to perform the Battlize Fire Drive (バトライズファイヤードライブ, Batoraizu Faiyā Doraibu) finisher. As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Ban has acquired a red-colored S.W.A.T. Mode vest to signify his membership in the Fire Squad. During the events of the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster, he acquires a variant of the SP License called the SP1 License (SP1ライセンス, Esu Pī Wan Raisensu), which allows him to transform into the armored Premiere Deka Red (プレミアデカレッド, Puremia Deka Reddo). While transformed, he wields the D-Sword Vega, which allows him to perform the Boost Slash (ブーストスラッシュ, Būsuto Surasshu) finisher. Ban is portrayed by Ryuji Sainei (載寧 龍二, Sainei Ryūji).
== Key people == The Santa Monica-based startup was founded in September 2011 by Trevor Bezdek and former Facebook executives Doug Hirsch and Scott Marlette. Marlette was one of the first 20 employees at Facebook and built Facebook's photo application. In 2005, Hirsch was the Vice President of Product at Facebook, working closely with Mark Zuckerberg. Bezdek and Hirsch served as co-chief executive officers until April 2023, when they stepped down from those roles and technology executive Scott Wagner was appointed interim chief executive officer. Bezdek became chair of the board, while Hirsch took on the role of chief mission officer. In December 2024, GoodRx announced that healthcare executive Wendy Barnes would become president and chief executive officer effective January 1, 2025. As of 2025, Barnes serves as the company's CEO, while Trevor Bezdek and Scott Wagner serve as co-chairs of the board, and Doug Hirsch remains involved as a co-founder and senior executive.
== Structure == The edited sites are found within the insulin growth factor binding domain of IGFBP7 and also Heparin binding domain. This region is also a site for proteolytic cleavage. Structural analysis of the edited sites determined that the two amino acids that corresponded to the edited sites are not directly involved in binding to IGF-1 but are found in regions flanking them. At position 78 in unedited version of the transcript there is an Arginine close to residue valine-49. This Valine is important in hydrophobic interaction of Phenylalanine of IGF-1. A substitution to a Glycine at this position is thought to introduce additional flexibility leading to a change of loop conformation, thereby disrupting the hydrophobic interaction that stabilises the complex. At amino acid position 98 the unedited transcript contains a lysine. This residue makes some non specific interactions via the aliphatic part of the side chain with Glu-38 of IGF-1. In the edited version the position is an arginine. The long side chain of which is thought to be able to maintain these weak interactions.
Sources: en.wikipedia.org
Pluralism and regulation of the media, such as through 'the licensing of broadcasting, television or cinema enterprises', have long been seen as essential to protect freedom of opinion and expression, to ensure that citizens have a more equal voice, and ultimately to support the universal 'right to take part in the government'. In almost all member states there is a well funded public, and independent broadcaster for TV and radio, and there are common standards for all TV and radio, which are designed to support open, fact-based discussion and deliberative democracy. However, the same standards have not yet been applied to equivalent internet television, radio or "social media" such as the platforms controlled by YouTube (owned by Alphabet), Facebook or Instagram (owned by Meta), or Twitter (owned by Elon Musk), all of which have spread conspiracy theories, discrimination, far-right, extremist, terrorist, and hostile military content.
=== Corporate management === Chipotle's team includes a residing corporate office of managers and its board of directors. Members of both teams are appointed to serve on committees: audit, compensation, and nominating and corporate governance. By late 2016, the top management team consisted of the chief executive officer, Steve Ells; the chief financial officer, Jack R. Hartung; the chief marketing and development officer, Mark Crumpacker. At that time, the board of directors consists of: Ells, Patrick Flynn, Albert Baldocchi, Neil Flanzraich, Darlene Friedman, Stephen Gillet, Kimbal Musk and John Charlesworth. On March 14, 2018, it was reported that Mark Crumpacker, who had previously been charged in a 2016 cocaine ring indictment, would be leaving the company. Ells was chairman of the company, and was chief executive officer until November 2017. He had a 1.25% stake in the company in 2010. The labor-market research firm Glassdoor reported that Ells earned $29 million in 2014, versus a median of $19,000 for Chipotle's workers, making the CEO-to-worker pay ratio 1522:1. On February 13, 2018, Chipotle announced that Taco Bell CEO Brian Niccol would replace Ells as CEO starting on March 5 while Ells would retain his chairman position. On March 6, 2020, Ells resigned as chairman and left the board of directors, breaking his final ties to the company. At the same time, Niccol was appointed chairman, and the size of the board was reduced from ten to seven directors. On August 13, 2024, Starbucks announced it was hiring Niccol as its next CEO.
Lyme disease can produce a broad range of symptoms. The incubation period is usually one to two weeks, but can be much shorter (days) or much longer (months to years). Lyme symptoms most often occur from May to September in the Northern Hemisphere because the nymphal stage of the tick is responsible for most cases.
Samples for dating need to be converted into a form suitable for measuring the 14C content; this can mean conversion to gaseous, liquid, or solid form, depending on the measurement technique to be used. Before this can be done, the sample must be treated to remove any contamination and any unwanted constituents. This includes removing visible contaminants, such as rootlets that may have penetrated the sample since its burial. Alkali and acid washes can be used to remove humic acid and carbonate contamination, but care has to be taken to avoid removing the part of the sample that contains the carbon to be tested.
Sources: en.wikipedia.org
=== Allegations of Forced Recruitment === Amid the political dispute between the TPLF-reinstated regional council and the federally recognized Tigray Interim Administration (TIA), reports emerged in 2026 alleging widespread forced military recruitment across parts of Tigray. On 4 June 2026, Human Rights First Ethiopia (HRFE) released an investigative report claiming that coercive recruitment campaigns and mass roundups (afesa) had occurred in several areas of Tigray, including the Northwestern, Central, and Eastern zones. The report documented testimonies from 27 witnesses, including family members, local officials, former recruits, and individuals who allegedly escaped conscription. According to the report, recruitment efforts targeted former Tigray Defense Forces members, households that had not previously contributed family members during the 2020–2022 conflict, and groups of young people gathered in public locations such as markets, mining sites, entertainment venues, and religious sites. HRFE alleged that some individuals were detained, transported to military facilities, or compelled to join military units against their will. The organization argued that such practices violated provisions of the Ethiopian Constitution, the African Charter on Human and Peoples' Rights, and international human rights instruments concerning arbitrary detention and forced labor.
Small-flowered Division: Flowers (1.5–)2–12(–18) cm across Armandii Group: Cultivars belonging to, or derived from, species classified in subsection Meyenianae (Tamura) M. Johnson, mainly C. armandii. Atragene Group: Cultivars belonging to, or derived from, species classified in subgenus Atragene (L.) Torrey & A. Gray, such as C. alpina, C. chiisanensis, C. fauriei, C. koreana, C. macropetala, C. ochotensis, C. sibirica, C. turkestanica. The former Alpina Group and Macropetala Group are included here. Historically, the Alpina Group was used for single-flowered cultivars, and double-flowered cultivars were assigned to the Macropetala Group. Cirrhosa Group: Cultivars belonging to, or derived mainly from, C. cirrhosa. Flammula Group: Cultivars with at least one parent belonging to, or derived from, species classified in section Flammula DC. (excluding subsection Meyenianae (Tamura)M. Johnson), such as C. angustifolia, C. flammula, C. recta, C. terniflora. Forsteri Group: Cultivars belonging to, or derived from, species classified in section Novae-zeelandiae M. Johnson (native to Australia and New Zealand) such as C. australis, C. foetida, C. forsteri, C. marata, C. marmoraria, C. paniculata, C. petriei. Heracleifolia Group: Cultivars with at least one parent belonging to, or derived from, species classified in subgenus Tubulosa (Decne.) Grey-Wilson, such as C. heracleifolia, C. stans, C. tubulosa. Integrifolia Group: Cultivars belonging to, or derived mainly from, C. integrifolia. Includes the Diversifolia Group (which covered C. × diversifolia (C. integrifolia × C.
=== Dawn of DC === When the United Planets take control of the Green Lantern Corps and quarantine Sector 2814, reassigning all of its Lanterns to elsewhere in the galaxy, John retires and chooses to remain on Earth with his mother, who is suffering from dementia. To protect her from grief, he creates a hard light construct of his deceased younger sister Ellie. When John is attacked and infected by the Radiant Dead, a necropathic group of corrupted Lanterns and constructs serving the Revenant Queen, he is forced to leave Earth to cure himself and stop the zombie-like horde from destroying the galaxy, teaming up with Caolán Shepherd, a Green Lantern from an alternate universe. John would later take on a starring role in Jeremy Adams' and Morgan Hampton's run on Green Lantern Corps (2025-present). In this run, John was notably reunited with his once long-deceased wife Katma Tui, with a version of Katma from Hypertime returning to the main DC Universe alive . In Geoffrey Thorne's mini-series, John had previously been split into two versions of himself, with one returning to the Green Lantern Corps and the other going off into the Dark Sectors to look for Katma. During Hampton's run, the John that had returned to the Green Lanterns died after sacrificing re-power the Source Battery on Oa, with his ring finding the other John having successfully found and living with Katma Tui.
== Personal life == Guillaume was married twice; first to Marlene Williams in 1955, with whom he had two sons. Guillaume's daughter was born in 1980. They divorced in 1984. He married Donna Brown in 1986. The couple had a daughter. He also fathered a daughter by a different mother, who was born in 1950. In 1999, Guillaume suffered a stroke while working on Sports Night at Walt Disney Studios in Burbank, California. The stroke was minor, causing relatively slight damage and little effect on his speech. After six weeks in the hospital, he underwent therapy consisting of walks and gym sessions.
A 1984 study that combined selegiline with phenylalanine reported remarkably high effectiveness in the treatment of depression similar to that with electroconvulsive therapy (ECT). However, selegiline in its original oral form was never further developed or approved for the treatment of depression. A few years after the discovery that selegiline was a selective MAO-B inhibitor, two Parkinson's disease researchers based in Vienna, Peter Riederer and Walther Birkmayer, realized that selegiline could be useful in Parkinson's disease. One of their colleagues, Moussa B. H. Youdim, visited Knoll in Budapest and took selegiline from him to Vienna. In 1975, Birkmayer's group published the first paper on the effect of selegiline in Parkinson's disease. Speculation, by József Knoll, that selegiline could be useful as an anti-aging and pro-sexual agent, began in the 1980s. The New York Times reported that selegiline was being used non-medically as a "smart drug" by 1992. Selegiline was first introduced for clinical use in Hungary in 1977. It was approved in the oral pill form under the brand name Jumex to treat Parkinson's disease. The drug was then introduced in the United Kingdom in 1982. In 1987, Somerset Pharmaceuticals in New Jersey, which had acquired the rights to develop selegiline in the United States, filed a New Drug Application (NDA) with the Food and Drug Administration (FDA) to market the drug for Parkinson's disease in this country. While the NDA was under review, Somerset was acquired in a joint venture by two generic drug companies, Mylan and Bolan Pharmaceuticals.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.